Regina Jehle - ABIVAX Socit VP Communications
| AAVXF Stock | USD 102.95 5.60 5.75% |
Insider
Regina Jehle is VP Communications of ABIVAX Socit Anonyme
| Phone | 33 1 53 83 08 41 |
| Web | https://www.abivax.com |
ABIVAX Socit Management Efficiency
The company has return on total asset (ROA) of (0.4368) % which means that it has lost $0.4368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.8647) %, meaning that it generated substantial loss on money invested by shareholders. ABIVAX Socit's management efficiency ratios could be used to measure how well ABIVAX Socit manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jillian Connell | Merus BV | N/A | |
| Finbar Larkin | Jazz Pharmaceuticals PLC | 66 | |
| Christopher MD | Nuvalent | 57 | |
| David Connolly | Rhythm Pharmaceuticals | N/A | |
| Brendan MBA | Crispr Therapeutics AG | 48 | |
| Michelle Gilson | Arcellx | 32 | |
| FACC MD | Cytokinetics | 58 | |
| Neeraj Teotia | Arcellx | 50 | |
| Joseph Shulman | Rhythm Pharmaceuticals | 50 | |
| Kevin PharmD | Axsome Therapeutics | 46 | |
| Mark Davis | Arrowhead Pharmaceuticals | N/A | |
| Howard Lovy | Arrowhead Pharmaceuticals | N/A | |
| Pamela Cramer | Rhythm Pharmaceuticals | 51 | |
| Vincent CFA | Arrowhead Pharmaceuticals | N/A | |
| Darlene Noci | Nuvalent | 48 | |
| Hunter MBA | Rhythm Pharmaceuticals | 56 | |
| William Roberts | Rhythm Pharmaceuticals | 45 | |
| Rodger MD | Crispr Therapeutics AG | 57 | |
| Alexander Bakker | Merus BV | 58 | |
| Cornelis Kruif | Merus BV | 61 | |
| Kate Aiken | Arcellx | N/A | |
Management Performance
| Return On Equity | -12.86 | |||
| Return On Asset | -0.44 |
ABIVAX Socit Anonyme Leadership Team
Elected by the shareholders, the ABIVAX Socit's board of directors comprises two types of representatives: ABIVAX Socit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIVAX. The board's role is to monitor ABIVAX Socit's management team and ensure that shareholders' interests are well served. ABIVAX Socit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIVAX Socit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Didier Blondel, CFO, Board Secretary | ||
| Alain Chevallier, Advisor | ||
| Philippe MD, Founder Director | ||
| Regina Jehle, VP Communications | ||
| Prof Ehrlich, Chief Officer | ||
| Paul Gineste, VP Operations | ||
| Anne Pascard, HR Mang | ||
| Raquel Lizarraga, Investor Mang | ||
| Pierre MBA, Chief Devel | ||
| Alexandra Pearce, Vice President and Head of Regulatory Affairs |
ABIVAX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ABIVAX Socit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.86 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | 4.66 % | |||
| Current Valuation | 165.28 M | |||
| Shares Outstanding | 22.3 M | |||
| Shares Owned By Insiders | 4.67 % | |||
| Shares Owned By Institutions | 57.27 % | |||
| Price To Earning | (7.88) X | |||
| Price To Book | 27.57 X | |||
| Price To Sales | 20.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in ABIVAX Pink Sheet
ABIVAX Socit financial ratios help investors to determine whether ABIVAX Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABIVAX with respect to the benefits of owning ABIVAX Socit security.